Literature DB >> 34511575

Associations of Serum Insulin-Like Growth Factor 1 with New Cardiovascular Events and Subsequent Death in Hemodialysis Patients: The DREAM Cohort.

Rino Nakaya1, Tetsuo Shoji2,3, Yuki Nagata2,3, Shinya Nakatani1, Katsuhito Mori4, Tomoaki Morioka1, Yoshihiro Tsujimoto5, Masanori Emoto1,3,4.   

Abstract

AIM: Patients with chronic kidney disease (CKD) have elevated risk of death from cardiovascular disease (CVD). A low serum insulin-like growth factor 1 (IGF-1) level is known to predict higher risk for all-cause mortality in incident dialysis patients, although it is unknown whether IGF-1 predicts cardiovascular outcomes.
METHODS: This was a prospective cohort study of maintenance hemodialysis patients followed up for 5 years. Serum IGF-1 levels were measured at baseline, and patients were divided into IGF-1 tertiles. The key outcomes were all-cause mortality, a composite of new CVD, and death after new CVD events. Additional outcomes were hospitalization for infection and subsequent death. Association was analyzed using Cox proportional hazards models.
RESULTS: In the 516 patients that were analyzed, we identified 106 all-cause deaths, 190 new CVD events, and 61 subsequent deaths. In addition, there were 169 hospitalizations for infection and 47 subsequent deaths. The risk of all-cause death was the highest in the lowest IGF-1 tertile, and this association remained significant in multivariable-adjusted models. Regarding CVD outcomes, IGF-1 was not associated with new CVD events but significantly associated with subsequent death in adjusted models. Similarly, IGF-1 was not an independent predictor of hospitalization for infection, but it predicted subsequent death.
CONCLUSIONS: A low IGF-1 level was not a significant predictor of new CVD events but an independent predictor of subsequent death in hemodialysis patients. Since similar associations with infection outcomes were observed, IGF-1 may be a biomarker of fragility or frailty in this population.

Entities:  

Keywords:  Cardiovascular disease; Chronic kidney disease; Dialysis; Frailty; Insulin-like growth factor 1

Mesh:

Substances:

Year:  2021        PMID: 34511575      PMCID: PMC9371757          DOI: 10.5551/jat.62992

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.394


  39 in total

1.  IGF-1 and survival in ESRD.

Authors:  Ting Jia; Thiane Gama Axelsson; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel; Abdul Rashid Qureshi
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

2.  Serum IL-6 and IGF-1 improve clinical prediction of functional decline after hospitalization in older patients.

Authors:  Marie de Saint-Hubert; Jacques Jamart; Gabriel Morrhaye; Henri J Martens; Vincent Geenen; Thi Kim Duy Vo; Olivier Toussaint; Christian Swine
Journal:  Aging Clin Exp Res       Date:  2010-05-06       Impact factor: 3.636

3.  The relationship between serum IGF-1, handgrip strength, physical performance and falls in elderly men and women.

Authors:  I C van Nieuwpoort; M C Vlot; L A Schaap; P Lips; M L Drent
Journal:  Eur J Endocrinol       Date:  2018-05-22       Impact factor: 6.664

4.  Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients.

Authors:  Tetsuo Shoji; Seiji Marubayashi; Takashi Shigematsu; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Ther Apher Dial       Date:  2014-12-19       Impact factor: 1.762

5.  Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. The Okinawa Dialysis Study (OKIDS) Group.

Authors:  K Iseki; K Fukiyama
Journal:  Nephrol Dial Transplant       Date:  2000-11       Impact factor: 5.992

6.  Decreased serum adrenal androgen dehydroepiandrosterone sulfate and mortality in hemodialysis patients.

Authors:  Ryusuke Kakiya; Tetsuo Shoji; Tomoshige Hayashi; Naoko Tatsumi-Shimomura; Yoshihiro Tsujimoto; Tsutomu Tabata; Hideaki Shima; Katsuhito Mori; Shinya Fukumoto; Hideki Tahara; Hidenori Koyama; Masanori Emoto; Eiji Ishimura; Yoshiki Nishizawa; Masaaki Inaba
Journal:  Nephrol Dial Transplant       Date:  2012-07-03       Impact factor: 5.992

7.  Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

Authors:  S M Orme; R J McNally; R A Cartwright; P E Belchetz
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

8.  Prevalence of antibody to hepatitis C virus in hemodialysis patients.

Authors:  J Hayashi; K Nakashima; W Kajiyama; A Noguchi; M Morofuji; Y Maeda; S Kashiwagi
Journal:  Am J Epidemiol       Date:  1991-09-15       Impact factor: 4.897

9.  Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease.

Authors:  Kayo Shinohara; Tetsuo Shoji; Masanori Emoto; Hideki Tahara; Hidenori Koyama; Eiji Ishimura; Takami Miki; Tsutomu Tabata; Yoshiki Nishizawa
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

10.  A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients.

Authors:  Erik Nilsson; Juan Jesus Carrero; Olof Heimbürger; Olof Hellberg; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin Kidney J       Date:  2015-11-26
View more
  2 in total

1.  Association of Reduced Free T3 to Free T4 Ratio with Lower Serum Creatinine in Japanese Hemodialysis Patients.

Authors:  Masaaki Inaba; Katsuhito Mori; Yoshihiro Tsujimoto; Shinsuke Yamada; Yuko Yamazaki; Masanori Emoto; Tetsuo Shoji
Journal:  Nutrients       Date:  2021-12-17       Impact factor: 5.717

2.  IGF-1 and Cardiovascular and Non-Cardiovascular Mortality Risk in Patients with Chronic Kidney Disease: A Model of "Malnutrition-Inflammation-Atherosclerosis Syndrome".

Authors:  Michio Shimabukuro
Journal:  J Atheroscler Thromb       Date:  2022-04-13       Impact factor: 4.394

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.